Gold prices edge higher on raised Fed rate cut hopes
FORT WORTH, Texas— Lantern Pharma Inc . (NASDAQ:LTRN) witnessed a notable stock sale by a major shareholder, as disclosed in a recent SEC filing. The timing is particularly interesting as InvestingPro data shows the stock has declined over 8% in the past week, though analysis suggests the company is currently undervalued. Leslie W. Kreis, along with associated entities including Cavu Management, LP and Cavu Advisors, LLC, executed a series of transactions on June 13, 2025, selling a total of 42,000 shares of common stock. The shares were sold at a weighted average price of $3.09, generating proceeds of approximately $123,600.
The entities involved in the transactions, such as Bios Fund I QP, LP, Bios Fund I, LP, and others, are managed and controlled by Mr. Kreis and his associates. Following these sales, the entities collectively hold significant remaining stakes in Lantern Pharma. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.86 and holds more cash than debt on its balance sheet.
The transactions were executed in multiple trades, with the stock prices ranging from $3.05 to $3.26. These sales reflect part of a broader strategy by the entities involved, which maintain substantial holdings in the company even after the sales.
Lantern Pharma, a biotech firm focused on precision oncology, continues to attract attention from investors, with its stock movements closely monitored by the market.
In other recent news, Lantern Pharma Inc. reported its financial results for the first quarter of 2025, highlighting a narrower net loss of $4.5 million compared to $5.4 million in the same period last year. The company attributes this improvement to strategic cost management and a reduction in research and development expenses. Lantern Pharma maintains a strong cash position of $19.7 million, which is expected to support operations through May 2026. The company’s key clinical trials, including those for LP-184 and LP300, are progressing, with significant milestones anticipated in 2025. Lantern Pharma is leveraging its AI platform, RADAR, to enhance its competitive position in precision oncology. In other developments, Lantern Pharma unveiled promising preclinical data for its drug candidate LP-184, targeting atypical teratoid rhabdoid tumors, a rare form of pediatric brain cancer. The data presented at a recent conference showed a substantial increase in median survival in mouse models, supporting the drug’s Rare Pediatric Disease Designation by the FDA. These recent advancements underscore Lantern Pharma’s ongoing efforts to advance its clinical pipeline and AI-driven drug discovery platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.